IVEVF News and Press, Inventiva SA From 03/08/22

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...

Inventiva S.A. (IVA) Q4 2021 Earnings Conference Call March 08, 2022 08:00 AM ET Company Participants Frédéric Cren - Chairman, Chief Executive Officer & Co-Founder Pierre Broqua - Chief Scientific Officer & Co-Founder Michael Cooreman - Chief Medical Officer Jean Volatier -...

Inventiva S.A. (IVA) Q2 2021 Results Conference Call September 21, 2021 08:00 AM ET Company Participants Frédéric Cren - Chairman, CEO and Co-Founder Pierre Broqua - CSO and Co-Founder Michael Cooreman - CMO Jean Volatier - CFO Conference Call Participants Lucy Codrington - Jefferie...

The following slide deck was published by Inventiva S.A. in conjunction with this event. For further details see: Inventiva (IVA) Investor Presentation - Slideshow

Inventiva S.A. (IVEVF) Q4 2020 Earnings Conference Call March 5, 2021 08:00 ET Company Participants Frédéric Cren - Chairman, Chief Executive Officer and Co-Founder Pierre Broqua - Chief Scientific Officer and Co-Founder Michael Cooreman - Chief Medical Officer Jean Volatier - Chief...

The following slide deck was published by Inventiva S.A. in conjunction with this event. For further details see: Inventiva (IVEVF) Investor Presentation - Slideshow

Investment Thesis Formulating the launch plans well ahead of the approval, Intercept Pharmaceuticals, Inc. ( ICPT ) caught completely off guard when the FDA refused to sign off OCA, a Intercept’s candidate for liver fibrosis in NASH. The agency, however, hasn’t completely ...

Introduction In March, I wrote an article about Genfit (NASDAQ: GNFT ) and the potential of its lead drug candidate Elafibranor in NASH. In my analysis, I underlined the huge upward potential but also underpinned the binary characteristic of the investment case. My recommendation was to ...

French biopharma Inventiva ( OTCPK:IVEVF ) has emerged as a new player in the pursuit of a treatment for nonalcoholic steatohepatitis (NASH). More news on: Inventiva S.A., Genfit SA, CymaBay Therapeutics, Inc., Healthcare stocks news, Read more ...

Introduction It is remarkable how few articles have been published about Genfit ( GNFT) lately on Seeking Alpha. The last articles dated from June and August last year. This is quite remarkable since the company is nearing its make-or-break moment and indicates that investors’ ...